Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...
Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback